Ginkgo Bioworks Holdings, Inc.
DNA
$7.71
-$0.14-1.78%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -49.06% | -23.84% | -56.39% | -11.75% | 0.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -49.06% | -23.84% | -56.39% | -11.75% | 0.75% |
| Cost of Revenue | -24.25% | -24.12% | 6.66% | 8.02% | -55.55% |
| Gross Profit | -52.03% | -23.75% | -66.21% | -18.13% | 18.78% |
| SG&A Expenses | -9.81% | -11.49% | -14.03% | -34.71% | -38.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.32% | -25.03% | -10.04% | -47.97% | -45.47% |
| Operating Income | 9.34% | 25.59% | -68.93% | 60.85% | 55.40% |
| Income Before Tax | 8.51% | 24.54% | -42.23% | 72.08% | 49.83% |
| Income Tax Expenses | -190.91% | -97.85% | 100.27% | -248.95% | 183.87% |
| Earnings from Continuing Operations | 8.70% | 24.91% | -43.18% | 72.24% | 49.79% |
| Earnings from Discontinued Operations | 14.63% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.20% | 24.91% | -43.18% | 72.24% | 45.18% |
| EBIT | 9.34% | 25.59% | -68.93% | 60.85% | 55.40% |
| EBITDA | 7.82% | 26.57% | -82.09% | 69.86% | 59.24% |
| EPS Basic | 17.32% | 29.20% | -34.44% | 74.00% | 49.35% |
| Normalized Basic EPS | 13.78% | 31.90% | -94.60% | 63.46% | 58.91% |
| EPS Diluted | 17.32% | 28.97% | -34.39% | 74.00% | 49.47% |
| Normalized Diluted EPS | 13.78% | 31.90% | -94.60% | 63.46% | 58.89% |
| Average Basic Shares Outstanding | 9.81% | 6.07% | 6.50% | 6.79% | 8.24% |
| Average Diluted Shares Outstanding | 9.81% | 6.07% | 6.48% | 6.78% | 8.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |